News
13 June 2017
CANTAB Research Grant 2017 – Results
The 2017 CANTAB Research Grant was once again overwhelmed with applications. All the research proposals received were such high quality it was another impossible task for our funding committee to review and narrow the proposals down. We received applications from across the globe from Hong Kong to Saint Lucia. But there could only be 3 awards.
Read on
7 June 2017
Speech recognition to improve clinical trial efficiency
Cambridge Cognition is pleased to announce its application of automatic speech recognition (“ASR”) technology to develop new products to enable scalable, language-based clinical assessment to reduce clinical trial variability and costs and increase overall clinical trial efficiency.
Read on
19 May 2017
Cambridge Cognition support the next tech masterminds
During a week focusing on employment skills, businesses were invited to Cambridge Regional College (CRC) to talk to students during its Computer Industry Week, running practical workshops on interview preparation and skills.
Read on
16 May 2017
Creator of CANTAB receives Gold Medal Award from The Society of Biological Psychiatry
Co-creator of CANTAB (Cambridge Neuropsychological Test Automated Battery) Professor Trevor Robbins is to receive the Gold Medal Award on May 19, 2017, at the 72nd Annual Meeting in San Diego, California. The award honours pioneering contributions in the field of biological psychiatry and significant and sustained work that extends knowledge in the field.
Read on
3 May 2017
Cambridge Cognition CSO named in Top 40 Healthcare Transformers
Company CSO honoured at this year's ceremony celebrating leading health-tech innovators.
Read on
16 March 2017
CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab
Cambridge Cognition today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.
Read on
8 March 2017
Design and rationale of the EBBINGHAUS trial
The Journal Clinical Cardiology has published on the design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of the human anti-PCSK9 monoclonal antibody evolocumab on cognitive function in patients with clinically evident cardiovascular disease receiving statin background lipid-lowering therapy1.
Read on
